Top

BMC Cancer

Published in:

01-12-2021 | Hepatocellular Carcinoma | Research article

Prognostic value of inflammation-based indices in patients with resected hepatocellular carcinoma

Authors: Weihao Kong, Mingwei Yang, Jianfeng Zhang, Ya Cheng, Tianxing Dai, Jian Zhang, Guoying Wang, Jianlin Zhang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

As is well recognized that inflammation plays a crucial role in the genesis and progression of various cancer. Here we investigate the prognostic value of a novel index: the combination of neutrophil to lymphocyte ratio and platelet distribution width (coNLR-PDW) in post-operation patients with resectable hepatocellular carcinoma (HCC).

Methods

The receiver operating characteristic (ROC) curve was utilized to determine the optimal cutoff values of continuous variables, including the neutrophil-lymphocyte ratio (NLR) and platelet distribution width (PDW). Kaplan-Meier method and the Log-rank test were used to compare survival differences across three groups stratified by the coNLR-PDW score. Univariate and multivariate Cox proportional hazard regression analyses were adopted to identify independent factors of HCC patient’s prognosis.

Results

1.59 and 13.0 were perceived as the optimal cutoff value for NLR and PDW based on the ROC curve, respectively. Kaplan-Meier method revealed that a higher coNLR-PDW score predicts poorer overall survival (OS) and disease-free survival (DFS) (P < 0.001). coNLR-PDW was demonstrated as an independent factor for both OS and DFS using Cox regression analysis in training and validation cohort.

Conclusion

coNLR-PDW is recognized as a valuable biomarker for predicting the survival of patients with HCC.

Available only for authorised users

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322.CrossRefPubMedPubMedCentral

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

Ni XC, Yi Y, Fu YP, He HW, Cai XY, Wang JX, et al. Prognostic value of the modified Glasgow prognostic score in patients undergoing radical surgery for hepatocellular carcinoma. Medicine. 2015;94(36):e1486. https://doi.org/10.1097/MD.0000000000001486.CrossRefPubMedPubMedCentral

Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134–46. https://doi.org/10.1016/j.critrevonc.2017.06.002.CrossRefPubMed

Huang W, Wang S, Zhang H, Zhang B, Wang C. Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer. Cancer Biol Med. 2018;15(1):88–96. https://doi.org/10.20892/j.issn.2095-3941.2017.0124.CrossRefPubMedPubMedCentral

Zhou Q, Huang F, He Z, Zuo MZ. Clinicopathological and prognostic significance of platelet count in patients with ovarian cancer. Climacteric. 2018;21(1):60–8. https://doi.org/10.1080/13697137.2017.1406911.CrossRefPubMed

Rao XD, Zhang H, Xu ZS, Cheng H, Shen W, Wang XP. Poor prognostic role of the pretreatment platelet counts in colorectal cancer: a meta-analysis. Medicine. 2018;97(23):e10831. https://doi.org/10.1097/MD.0000000000010831.CrossRefPubMedPubMedCentral

Chen S, Na N, Jian Z. Pretreatment platelet count as a prognostic factor in patients with pancreatic cancer: a systematic review and meta-analysis. OncoTargets Ther. 2018;11:59–65. https://doi.org/10.2147/OTT.S147715.CrossRef

10.

Abu-Zaid A, Alomar O, Salem H. Preoperative elevated platelet count as a prognostic factor in vulvar squamous cell Cancer: a mini-review. Cureus. 2018;10(3):e2279. https://doi.org/10.7759/cureus.2279.CrossRefPubMedPubMedCentral

11.

Long Y, Wang T, Gao Q, Zhou C. Prognostic significance of pretreatment elevated platelet count in patients with colorectal cancer: a meta-analysis. Oncotarget. 2016;7(49):81849–61. https://doi.org/10.18632/oncotarget.13248.CrossRefPubMedPubMedCentral

12.

Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(4):5379–87.PubMedPubMedCentral

13.

Gu L, Li H, Gao Y, Ma X, Chen L, Li X, et al. The association of platelet count with clinicopathological significance and prognosis in renal cell carcinoma: a systematic review and meta-analysis. PLoS One. 2015;10(5):e0125538. https://doi.org/10.1371/journal.pone.0125538.CrossRefPubMedPubMedCentral

14.

Cheng S, Han F, Wang Y, Xu Y, Qu T, Ju Y, et al. The red distribution width and the platelet distribution width as prognostic predictors in gastric cancer. BMC Gastroenterol. 2017;17(1):163. https://doi.org/10.1186/s12876-017-0685-7.CrossRefPubMedPubMedCentral

15.

Li N, Diao Z, Huang X, Niu Y, Liu T, Liu ZP, et al. Increased platelet distribution width predicts poor prognosis in melanoma patients. Sci Rep. 2017;7(1):2970. https://doi.org/10.1038/s41598-017-03212-y.CrossRefPubMedPubMedCentral

16.

Takeuchi H, Abe M, Takumi Y, Hashimoto T, Kobayashi R, Osoegawa A, et al. The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer. PLoS One. 2017;12(12):e0189166. https://doi.org/10.1371/journal.pone.0189166.CrossRefPubMedPubMedCentral

17.

Xie X, Zeng X, Cao S, Hu X, Shi Q, Li D, et al. Elevated pretreatment platelet distribution width and platelet count predict poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017;8(62):106089–97. https://doi.org/10.18632/oncotarget.22528.CrossRefPubMedPubMedCentral

18.

Zhang H, Liu L, Fu S, Liu YS, Wang C, Liu T, et al. Higher platelet distribution width predicts poor prognosis in laryngeal cancer. Oncotarget. 2017;8(29):48138–44. https://doi.org/10.18632/oncotarget.18306.CrossRefPubMedPubMedCentral

19.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

20.

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.CrossRefPubMed

21.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. https://doi.org/10.1016/j.cell.2010.01.025.CrossRefPubMedPubMedCentral

22.

Ji F, Liang Y, Fu SJ, Guo ZY, Shu M, Shen SL, et al. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI). BMC Cancer. 2016;16(1):137. https://doi.org/10.1186/s12885-016-2189-1.CrossRefPubMedPubMedCentral

23.

Zheng J, Cai J, Li H, Zeng K, He L, Fu H, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem. 2017;44(3):967–81. https://doi.org/10.1159/000485396.CrossRefPubMed

24.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.CrossRefPubMed

25.

Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137–46. https://doi.org/10.1172/JCI31405.CrossRefPubMedPubMedCentral

26.

Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 2009;10(9):877–84. https://doi.org/10.1016/S1470-2045(09)70186-X.CrossRefPubMed

27.

Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thrombosis Haemostasis. 2011;9(2):237–49. https://doi.org/10.1111/j.1538-7836.2010.04131.x.CrossRef

28.

Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost. 2014;40(3):296–305. https://doi.org/10.1055/s-0034-1370767.CrossRefPubMed

29.

Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer. 2013;109(2):401–7. https://doi.org/10.1038/bjc.2013.350.CrossRefPubMedPubMedCentral

30.

Xia W, Chen W, Tu J, Ni C, Meng K. Prognostic value and Clinicopathologic features of platelet distribution width in Cancer: a meta-analysis. Med Sci Monit. 2018;24:7130–6. https://doi.org/10.12659/MSM.913040.CrossRefPubMedPubMedCentral

31.

Song X, Zhu H, Pei Q, Tan F, Li C, Zhou Z, et al. Significance of inflammation-based indices in the prognosis of patients with non-metastatic colorectal cancer. Oncotarget. 2017;8(28):45178–89. https://doi.org/10.18632/oncotarget.16774.CrossRefPubMedPubMedCentral

Title: Prognostic value of inflammation-based indices in patients with resected hepatocellular carcinoma
Authors: Weihao Kong
Mingwei Yang
Jianfeng Zhang
Ya Cheng
Tianxing Dai
Jian Zhang
Guoying Wang
Jianlin Zhang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08153-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

The long-term survival outcomes of gastric cancer patients with total intravenous anesthesia or inhalation anesthesia: a single-center retrospective cohort study

ROR1 and ROR2 expression in pancreatic cancer

A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study

Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study

Identification and development of an independent immune-related genes prognostic model for breast cancer

A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer